Journal of Antimicrobial Chemotherapy (1999) 43, 389-397
© 1999 The British Society for Antimicrobial Chemotherapy
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection
a RA Cowley Shock Trauma Center, University of Maryland, Baltimore, MD; b Dayton VA Medical Center, Wright State University, Dayton, OH; c Division of Surgical Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH; d Wyeth-Ayerst Research, Radnor, PA; e Wyeth-Ayerst Research, current address: Pfizer Central Research, Groton, CT, USA
An open-label, randomized, comparative, multi-centre study was conducted at 25 centres in the USA and Canada to compare the safety and efficacy of piperacillin/tazobactam plus tobramycin with ceftazidime plus tobramycin in patients with lower respiratory tract infections. Piperacillin/ tazobactam (3 g/375 mg) every 4 h or ceftazidime (2 g) every 8 h were administered iv for a minimum of 5 days. Tobramycin (5 mg/kg/day) given in divided doses every 8 h was administered to all patients. Patients with Pseudomonas aeruginosa isolated from respiratory secretions at baseline were to continue tobramycin for the duration of the study. Tobramycin could be discontinued in other patients after the baseline culture results were known. A total of 300 patients was randomized, 155 into the piperacillin/tazobactam group and 145 into the ceftazidime group. Of these, 136 patients (78 in the piperacillin/tazobactam group and 58 in the ceftazidime group) were considered clinically evaluable. Both groups were comparable for age, sex, duration of treatment and other demographic features. The clinical success rate in evaluable patients was significantly greater (P = 0.006) in the piperacillin/tazobactam treatment group (58/78; 74%) than in the ceftazidime group (29/58; 50%). Eradication of the baseline pathogen was significantly greater (P = 0.003) in the piperacillin/tazobactam group (66%) than in the ceftazidime group (38%). The clinical and bacteriological responses of those patients with nosocomial pneumonia were similar to the overall results. Twelve (7.7%) piperacillin/tazobactam-treated patients and 24 (17%) ceftazidime-treated patients died during the study (P = 0.03). Seven of the 24 deaths in the ceftazidime treatment group but only one of the 12 deaths in the piperacillin/ tazobactam treatment group were directly related to failure to control infection. The majority of adverse events were thought by the investigator to be attributable to the patients' underlying disease and not drug related. In this study, piperacillin/tazobactam plus tobramycin was shown to be more effective and as safe as ceftazidime plus tobramycin in the treatment of patients with nosocomial LRTI.
* Corresponding author. Tel: +1-410-328-3656; Fax: +1-410-328-6826.
The Piperacillin/tazobactam Nosocomial Pneumonia Study Group: A. Erickson, Providence,
RI; R. A. Khakoo, Morgantown, WV; B. Suh, Philadelphia, PA; J. Wellman, Atlanta, GA; S.
Jenkinson, San Antonio, TX; C. Crim, St Louis, MO; N. Kirmani, Maywood, IL, D. Smith,
Kansas City, MO; D. W. Gump, Burlington, VT; G. T. Valainis, Spartanburg, SC; L. A. Von
Behren, Springfield, IL; W. J. Holloway, Wilmington, DE; B. E. Sieger, Orlando, FL; M. A.
Young, Washington, DC; S. J. Goodnight-White, Houston, TX; P. S. Barie, New York, NY; L.
D. Thrupp, Orange, CA, USA; T. J. Louie, Calgary, Alberta; D. Grimard, Chicoutimi, Quebec;
A. Y. Martel, Ste-Foy, Quebec; S. Lambert, Quebec, Quebec; R. Boileau, Sherbrooke, Quebec,
Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 388 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Mehta and M. S. Niederman Nosocomial Pneumonia in the Intensive Care Unit: Controversies and Dilemmas J Intensive Care Med, July 1, 2003; 18(4): 175 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Brun-Buisson Antibiotic Therapy of Ventilator-Associated Pneumonia: In Search of the Magic Bullet Chest, March 1, 2003; 123(3): 670 - 673. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Fowler, K. E. Flavin, J. Barr, A. B. Weinacker, J. Parsonnet, and M. K. Gould Variability in Antibiotic Prescribing Patterns and Outcomes in Patients With Clinically Suspected Ventilator-Associated Pneumonia Chest, March 1, 2003; 123(3): 835 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Lynch III Hospital-Acquired Pneumonia : Risk Factors, Microbiology, and Treatment Chest, February 1, 2001; 119 (2009): 373S - 384S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fiel Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia Chest, February 1, 2001; 119 (2009): 412S - 418S. [Abstract] [Full Text] [PDF]
|
|